RxDoctor Payments Data

Victoria Wolfgramm, MD

Family Medicine · Knoxville, TNNPI 1174693212

Payments from drug & device makers

$1,814in general payments, 2019–2025

Across 100 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$368
  • Amgen$335
  • Intuitive Surgical$243
  • AstraZeneca$135
  • Lilly USA, LLC$116
  • Pfizer$109
  • plus $507 from 17 others

What the payments were for

  • Food & beverage$1,814100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,814 in reported general payments places this provider in the 65th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$51,068
Medicare patients
109
Services billed
1,431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide26$28,330
OzempicSemaglutide17$22,874
TradjentaLinagliptin15$10,180
Estradiol16$655
Bupropion XlBupropion Hcl26$603
Duloxetine Hcl28$590
Atorvastatin Calcium34$404
Lisinopril51$404
Levothyroxine Sodium58$363
Azelastine Hcl13$347
Rosuvastatin Calcium23$340
Buspirone Hcl27$310
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$309
Simvastatin17$302
Gabapentin25$290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$116$28,33026 claims
Novo NordiskOzempic$368$22,87417 claims
Boehringer IngelheimTradjenta$14$10,18015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →